VEA
VTYX

Virtus ETF Advisers’s Ventyx Biosciences VTYX Stock Holding History

Virtus ETF Advisers’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,825
Closed -$98.1K – 465
2023
Q3 		$98.1K Sell
2,825
-278
-9% -$9.61K 0.06% 335
2023
Q2 		$102K Buy
3,103
+123
+4% +$4.24K 0.06% 372
2023
Q1 		$99.8K Sell
2,980
-1,145
-28% -$44.5K 0.05% 339
2022
Q4 		$135K Sell
4,125
-3,898
-49% -$115K 0.07% 378
2022
Q3 		$280K Buy
8,023
+53
+0.7% +$1.17K 0.11% 280
2022
Q2 		$97K Buy
+7,970
New +$119K 0.04% 431

Other funds holding VTYX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Virtus ETF Advisers's VTYX Position: Q4 2023 in Review

Virtus ETF Advisers sold out of Ventyx Biosciences (VTYX) in Q4 2023, closing a stake of 2,825 shares — an estimated $98.1K sold.

Virtus ETF Advisers first reported a position in VTYX in Q2 2022 and held it in 6 quarters. The position peaked at $280K in Q3 2022. 121 funds tracked by Wall St. Rank hold VTYX as of Q4 2023.

  • Virtus ETF Advisers reported no remaining Ventyx Biosciences position as of Q4 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 2,825 Ventyx Biosciences shares in Q4 2023, an estimated $98.1K.
  • Virtus ETF Advisers first reported a position in Ventyx Biosciences in Q2 2022 and held it in 6 quarters.
  • Virtus ETF Advisers's Ventyx Biosciences position peaked at $280K in Q3 2022.
  • 121 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2023.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.